Guidelines Suggest Two-Stage Strategy to Identify Diabetes Risk
The strategy consists of a risk assessment, followed, where necessary, by a blood test to confirm whether people have the disease, or are at high risk of developing it.
Read MorePosted by Clinical Lab Products | Aug 15, 2012 | Diabetes & Metabolic Diseases |
The strategy consists of a risk assessment, followed, where necessary, by a blood test to confirm whether people have the disease, or are at high risk of developing it.
Read MorePosted by Clinical Lab Products | Aug 7, 2012 | Controls, Quality Systems |
Blood-Based Control Product stablity provides increased flexibility The Dropper® A1c Diabetes Control from Quantimetrix, Redondo Beach, Calif, is a liquid, human blood-based control for laboratory and point-of-care (POCT) hemoglobin A
Read MorePosted by Clinical Lab Products | Aug 6, 2012 | Miscellaneous |
Judy O’Rourke As we’re putting this issue together for you, I’m still sorting through all of the materials acquired during the AACC 2012 annual meeting and expo, from which I returned barely a week ago. It was great seeing many familiar
Read MorePosted by Clinical Lab Products | Aug 4, 2012 | Diabetes & Metabolic Diseases, Research |
Using glycated albumin together with HbA1c, we can make the next positive step in providing better care for all people with diabetes
Read MorePosted by Clinical Lab Products | Jul 2, 2012 | Blood Gas Analyzers, Clinical Chemistry, Clinical Chemistry Analyzers, Clinical Chemistry Test Kits, Electrolytes, Miscellaneous |
As the acuity of patients seen in the hospital increases, point-of-care testing for blood gases and other critical care tests continues to expand
Read More